Citations

Showing 10 of 107966 citations.

Extensor Pollicis Longus Tendon Rupture With Concomitant Electrodiagnostic and MRI Findings of Posterior Interosseous Nerve Palsy
Lin, James S. , Kakar, Sanjeev , Shin, Alexander Y. , Bishop, Allen T. , Shin, Alexander Y , Kakar, Sanjeev , Bishop, Allen T

Mayo Clinic

JBJS Case Connector | January 16, 2025 | Volume: 15 | Issue: 1 | Pages: No page available

10.2106/jbjs.cc.24.00344 | PMID 39819640 Get It

Cases: Two patients with spontaneous loss of thumb interphalangeal joint extension were referred after history, electrodiagnostic, and/or magnetic resonance imaging (MRI) findings were felt to demonstrate a posterior interosseous nerve (PIN) palsy. Subsequent physical examination and additional directed studies suggested an alternative explanation: rupture of the extensor pollicis longus (EPL) tendon, subsequently confirmed at surgery. An extensor indicis proprius to EPL transfer restored thumb function. Conclusion: Electrodiagnostic and MRI changes consistent with diffuse PIN palsy may occur in the setting of EPL rupture. An accurate diagnosis of EPL dysfunction requires careful physical examination and confirmatory imaging. Further study of this previously unreported phenomenon is required.
Vascularized Iliac Crest Bone Graft for the Reconstruction of Anterior Vertebral Corpus Defects: A Literature Review and Cadaveric Feasibility Study
Jeger, Jonathan L. , Martínez, Christian , Simoni, Alec , Rebecca, Alanna M. , Winocour, Sebastian, Ropper, Alexander E., Bohl, Michael A. , Casey, William J., Kalani, Maziyar A. , Reece, Edward M., Martinez, Casey , Martinez, Casey J, Shvedova, Maria, Rebecca, Alanna, Kalani, Maziyar, Jeger, Jonathan L , Shvedova, Maria

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | January 16, 2025 | Volume: 13 | Issue: 1 | Pages: e6380

10.1097/gox.0000000000006380 | PMID 39823026 Get It

Background: Vertebral body defects pose a significant challenge in spinal reconstructive surgery. Compression fractures of the vertebral corpus are typically treated with vertebral augmentation procedures. There are significant risks associated with the introduction of foreign material in the spine, including infection and pseudarthrosis. Vascularized bone grafts (VBGs) have become a popular alternative for spinal reconstruction in the last decade thanks to their robust blood supply and autologous nature. VBGs have been described predominantly for the reconstruction of posterior vertebral defects. The objective of this study is to describe a novel procedure for the reconstruction of vertebral corpus defects in the lumbar and distal thoracic spine. Methods: This is a cadaveric anatomy study. The authors performed the novel surgical technique on an anonymized cadaveric donor in the prone position and recorded the procedure through clinical photography. Consent for the procedure and photography was obtained from the Center for Procedural Innovation. Results: A 5-cm-long posterior iliac crest VBG (IC-VBG) was successfully harvested on a pedicle of the quadratus lumborum muscle. The VBG was rotated and mobilized anteromedially to the vertebral corpus. In this donor, the IC-VBG could be inset with minimal tension anywhere along the vertebral bodies of the spine from the L5 to the T9 level. Conclusions: A rotated, anteromedially mobilized IC-VBG represents a novel technique for reconstruction of the anterior vertebral corpus of the lumbar and distal thoracic spine with a lower risk of infection and pseudarthrosis than reconstruction with foreign materials.
A Flexible Framework for Synthesizing Categorical Sequences with Application to Human Activity Patterns
Huang, Zuofu , Wolfson, Julian , Fulkerson, Jayne A. , Chen, Helen N., Wolfson, Julian , Demmer, Ryan T.

Mayo Clinic

Journal of Computational and Graphical Statistics | January 16, 2025 | Volume: 34 | Issue: 4 | Pages: 1410-1418

10.1080/10618600.2025.2450461 Get It

Correlating autonomic physiology with symptoms of autonomic dysreflexia after spinal cord injury
Higano, Jennifer Dens , Burns, Kathryn , Smith, Geoffrey , Solinsky, Ryan , Dens Higano, Jennifer , Solinsky, Ryan

Mayo Clinic

PM&R | January 16, 2025 | Volume: 17 | Issue: 5 | Pages: 478-484

10.1002/pmrj.13295 | PMID 39817508 Get It

AbstractBackgroundIndividuals with spinal cord injury (SCI) commonly have autonomic dysreflexia (AD) with increased sympathetic activity. After SCI, individuals have decreased baroreflex sensitivity and increased vascular responsiveness.ObjectiveTo evaluate the relationship between baroreflex and blood vessel sensitivity with AD symptoms.DesignCase control.SettingTertiary academic center.Patients14 individuals with SCI, 17 matched uninjured controls.InterventionsAll participants quantified AD symptoms using the Autonomic Dysfunction Following SCI (ADFSCI)‐AD survey. Participants received three intravenous phenylephrine boluses, reproducibly increasing systolic blood pressure (SBP) 15–40 mmHg. Continuous heart rate (R‐R interval, ECG), beat‐to‐beat blood pressures (Finapres), and popliteal artery flow velocity were recorded. Vascular responsiveness (α1 adrenoreceptor sensitivity) and heart rate responsiveness to increased SBP (baroreflex sensitivity) were calculated.Main Outcome MeasuresBaroreflex sensitivity after increased SBP; Vascular responsiveness through quantified mean arterial pressure (MAP) 2‐minute area under the curve and change in vascular resistance.ResultsSCI and control cohorts were well matched with mean age 31.9 and 29.6 years (p = .41); 21.4% and 17.6% female, respectively. Baseline MAP (p = .83) and R‐R interval (p = .39) were similar. ADFSCI‐AD scores were higher following SCI (27.9 ± 22.9 vs. 4.2 ± 2.9 in controls, p = .002). To quantify SBP response, MAP area under the curve was normalized to dose/body weight. Individuals with SCI had significantly larger responses (0.26 ± 0.19 mmHg*s/kg*μg) than controls (0.06 ± 0.06 mmHg*s/kg*μg, p = .002). Similarly, leg vascular resistance increased after SCI (24% vs. 6% to a normalized dose, p = .007). Baroreflex sensitivity was significantly lower after SCI (15.0 ± 8.3 vs. 23.7 ± 9.3 ms/mmHg, p = .01). ADFSCI‐AD subscore had no meaningful correlation with vascular responsiveness (R2 = 0.008) or baroreflex sensitivity (R2 = 0.092) after SCI.ConclusionsAlthough this confirms smaller previous studies suggesting increased α1 adrenoreceptor sensitivity and lower baroreflex sensitivity in individuals with SCI, contrary to our hypothesis these differences lacked correlation to increased symptoms of AD. Further research into physiologic mechanisms is needed to explain why some individuals with SCI develop symptoms.
PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Andrews, Jack R. , Kim, Yohan , Horjeti, Edlira , Arafa, Ali , Bruycker, Aurélie De , Phillips, Ryan , Song, Daniel Y. , Sartor, Oliver , Orme, Jacob J. , Chaudhuri, Aadel A. , Kiess, Ana P. , Sutera, Philip , Mercier, Carole , Arafa, Ali T. , Gunn, Heather , De Bruycker, Aurélie , Phillips, Ryan , Song, Daniel , Childs, Daniel S , Sartor, A Oliver , Orme, Jacob J , Chaudhuri, Aadel A , Tran, Phuoc T , Kiess, Ana , Sutera, Philip , Mercier, Carole , Ost, Piet , Park, Sean S , Lucien, Fabrice , Gunn, Heather , Childs, Daniel S. , Park, Sean S. , Lucien, Fabrice

Mayo Clinic

Clinical Cancer Research | January 16, 2025 | Volume: 31 | Issue: 6 | Pages: 1142-1149

10.1158/1078-0432.ccr-24-3027 | PMID 39820657 Get It

Abstract Purpose: Two randomized clinical trials (STOMP and ORIOLE) demonstrated that stereotactic ablative radiotherapy (SABR) can prolong androgen-deprivation therapy–free survival or progression-free survival (PFS) in patients with metachronous oligometastatic castration-sensitive prostate cancer (omCSPC). Although most patients with omCSPC have a more modest delay in progression, a small subset achieves a durable response following SABR. We investigated the prognostic and predictive value of circulating prostate-specific membrane antigen-positive (PSMA+) extracellular vesicles (EV) and PSA in a biomarker correlative study using blood samples from three independent patient cohorts. Experimental Design: Plasma samples from 46 patients with omCSPC on the ORIOLE trial and 127 patients with omCSPC on the STOMP trial protocol treated with SABR were included in the study. Pre-SABR PSMA+EV levels (EV/mL) were measured by nanoscale flow cytometry. Kaplan–Meier curves and logistic regression models were used to determine the association of PSMA+EV and PSA levels with clinical outcomes. Results: In the pooled cohorts, the median biochemical PFS were 26.1 and 15.0 months (P = 0.005), and the median radiographic PFS were 36.0 and 25.0 months (P = 0.003) for PSMA+EV-low and -high groups, respectively. The combination of pre-SABR low levels of both PSMA+EV and PSA was associated with a lower risk of radiographic progression (HR, 0.34, 95% confidence interval, 0.18–0.58; P = 0.0002). In the ORIOLE cohort, which included both an SABR arm and an observation arm, low PSMA+EV was predictive of benefit from SABR (P = 0.012). Conclusions: PSMA+EV is a novel prognostic and predictive biomarker of radiographically occult tumor burden in omCSPC. PSMA+EV may inform clinical decisions about identifying patients who will achieve a durable benefit from consolidative SABR alone.
Development of an Innovative Decision-Aid to Better Align Patients’ Implantable Cardioverter Defibrillator Shock Status With Goals of Care
Chen, Christine , Godfrey, Sarah , Newcomer, Kelley , Garrett, Brenden, Zhang, Jingwen , Patel, Nakul, Viamontes, Christopher G. , Shah, Nainesh , Patel, Nimesh , Chen, Christine L , Alvarez, Kristin , Garrett, Brenden , Patel, Nakul , Viamontes, Christopher , Shah, Nainesh , Patel, Nimesh S , Sulistio, Melanie S , Godfrey, Sarah , Alvarez, Kristin , Kelly, Megan M., Sulistio, Melanie S.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | January 16, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1161/circoutcomes.124.011544 | PMID 39817335 Get It

Reevaluating Anti-Inflammatory Therapy: Targeting Senescence to Balance Anti-Cancer Efficacy and Vascular Disease
Casso-Chapa, Bernardo , Le, Nhat‐Tu , Palaskas, Nicolas L. , Nead, Kevin T. , Eutsey, Lydia P., Samanthapudi, Venkata Subrahman K, Osborn, Abigail M., Mejia, Gilbert, Hoang, O.N. , Herrmann, Joerg, Kirkland, James L. , Chini, Eduardo N. , Yusuf, Syed Wamique , Iliescu, Cezar , Lorenzi, Philip L. , Chau, Khanh , Mendoza, Keila Carolina Ostos , Schadler, Keri , Le, Nhat-Tu , Palaskas, Nicolas L , Nead, Kevin T , Lee, Jonghae , Mejia, Gilbert , Hoang, Oanh , Lin, Steven H , Deswal, Anita M , Wang, Guangyu , Kirkland, James L , Krishnan, Sunil , Wehrens, Xander H T , Yusuf, Syed Wamique , Iliescu, Cezar A , Jain, Abhishek , Burks, Jared K , Seeley, Erin , Lorenzi, Philip L , Chau, Khanh M , Ostos-Mendoza, Keila C , Grumbach, Isabella M , Brookes, Paul S , Hanssen, Nordin M J , de Winther, Menno P J , Yvan-Charvet, Laurent , Kotla, Sivareddy , Schadler, Keri , Abe, Jun-Ichi , González, Norma Alicia Vazquez, Osborn, Abigail M., Lee, Jonghae , Lin, Steven H. , Herrmann, Joerg, Wang, Guangyu , Wehrens, Xander H.T. , Winther, Menno P.J. de , Kotla, Sivareddy

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | January 16, 2025 | Volume: 45 | Issue: 3 | Pages: 372-385

10.1161/atvbaha.124.319870 | PMID 39817327 Get It

Modulating immune function is a critical strategy in cancer and atherosclerosis treatments. For cancer, boosting or maintaining the immune system is crucial to prevent tumor growth. However, in vascular disease, mitigating immune responses can decrease inflammation and slow atherosclerosis progression. Anti-inflammatory therapy, therefore, presents a unique dilemma for cancer survivors: while it may decrease cardiovascular risk, it might also promote cancer growth and metastasis by suppressing the immune response. Senescence presents a potentially targetable solution to this challenge; senescence increases the risk of both cancer therapy resistance and vascular disease. Exercise, notably, shows promise in delaying this premature senescence, potentially improving cancer outcomes and lowering vascular disease risk post-treatment. This review focuses on the long-term impact of cancer therapies on vascular health. We underscore the importance of modulating senescence to balance cancer treatment’s effectiveness and its vascular impact, and we emphasize investigating the role of exercise-mediated suppression of senescence in improving cancer survivorship.
Risk of Post-polypectomy Bleeding After Colorectal Endoscopic Mucosal Resection in Patients With Cirrhosis: A Propensity-Matched Analysis of the US Collaborative Network
Beran, Azizullah , Elfert, Khaled , Patel, Feenalie N. , Mohamed, Mouhand , Ramai, Daryl , Canakis, Andrew , Thakkar, Shyam , Rex, Douglas K. , Bhavsar‐Burke, Indira , Guardiola, John , Guardiola, John J , Canakis, Andrew , Mohamed, Mouhand F H

Mayo Clinic

American Journal of Gastroenterology | January 16, 2025 | Volume: 120 | Issue: 11 | Pages: 2687-2691

10.14309/ajg.0000000000003322 | PMID 39950371 Get It

INTRODUCTION: Data on the risk of post-polypectomy bleeding after endoscopic mucosal resection (EMR) in patients with cirrhosis are limited. METHODS: This retrospective cohort study used the US Collaborative Network to assess post-polypectomy bleeding risk after colorectal EMR in patients with cirrhosis compared with controls. Using one-to-one propensity score matching, the primary outcome measured was bleeding within 30 days post-EMR. The bleeding risk was further stratified by cirrhosis severity (compensated and decompensated). RESULTS: After propensity score matching, each cohort included 2,381 patients. Patients with cirrhosis had a higher risk of post-polypectomy bleeding (odds ratio [OR] 1.38, 95% confidence interval [CI] 1.05–1.82, P = 0.02). However, endoscopic reinterventions for hemostasis were similar between cirrhosis and control cohorts (OR 1.20, 95% CI 0.71–2.05, P = 0.50). The post-polypectomy bleeding risk was significantly higher in patients with decompensated cirrhosis (OR 1.65, 95% CI 1.12–2.42, P = 0.01), while those with compensated cirrhosis showed no increased risk of post-polypectomy bleeding (OR 1.15, 95% CI 0.85–1.54, P = 0.37). DISCUSSION: The post-polypectomy bleeding risk was higher in patients with decompensated cirrhosis, while the bleeding risk was not increased in those with compensated disease. Optimizing patients with cirrhosis, especially with decompensated disease, before colorectal EMR and monitoring for post-procedure bleeding remain important. A conservative, supportive approach to managing bleeding in patients with cirrhosis may be as effective as in those without cirrhosis.
Venetoclax in combination with fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin (FLAG-Ida) in patients with acute leukemia of ambiguous lineage and acute lymphoblastic leukemia
Tessier, Steven , Gangat, Naseema , Begna, Kebede H. , Saliba, Antoine N. , Mangoankar, Abhishek A., Patnaik, Mrinal M. , Al‐Kali, Aref , Alkhateeb, Hassan B. , Saliba, Antoine N. , Saliba, Antoine N , Alkhateeb, Hassan B , Saliba, Antoine N , McCullough, Kristen , Shah, Meera , Hogan, William J.

Mayo Clinic

Leukemia & Lymphoma | January 16, 2025 | Volume: 66 | Issue: 4 | Pages: 780-784

10.1080/10428194.2024.2443017 | PMID 39817316 Get It

Is Topical Tranexamic Acid Effective in Reducing Hematoma and Seroma in Breast Surgery? A Systematic Review and Meta-analysis
Hashemi, Ammar S.A., Hussein, Sara , Alshehab, Zainab H., Hussein, Sara M., Sharaf, Basel A, Qurashi, Abdullah A. Al , Kreutz‐Rodrigues, Lucas , Sharaf, Basel

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | January 16, 2025 | Volume: 13 | Issue: 1 | Pages: e6442

10.1097/gox.0000000000006442 | PMID 39823029 Get It

Background: Postoperative fluid-related complications, such as hematoma and seroma formation, are common concerns in breast surgery, adversely affecting surgical outcomes and patient recovery. Topical tranexamic acid (TXA) has emerged as a promising intervention to minimize bleeding while reducing systemic adverse effects linked to intravenous administration. However, evidence on the efficacy of topical TXA in breast surgery remains sparse. Methods: This systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. English-language databases were searched through April 2024 to identify randomized controlled trials and cohort studies assessing the effects of topical TXA on postoperative outcomes in breast surgery, including hematoma, seroma, infection rates, and drain output/duration. Results: Six studies, encompassing 823 patients and 1477 breasts, were included. Subgroup meta-analysis demonstrated a statistically significant reduction in hematoma rates in patients who underwent mastectomy (risk ratio [RR] = 0.14; 95% confidence interval [CI], 0.03–0.78; P = 0.02), but not in patients who underwent breast reduction (RR = 0.76; 95% CI, 0.08–7.08; P = 0.24). No significant differences were found in overall hematoma rates (RR = 0.32; 95% CI, 0.08–1.195; P = 0.09), seroma formation (RR = 1.22; 95% CI, 0.99–1.51; P = 0.07), or infection rates (RR = 0.85; 95% CI, 0.46–1.56; P = 0.59). Conclusions: Topical TXA significantly reduced hematoma rates in patients who underwent mastectomy but showed no significant effect on other outcomes. Larger studies with standardized methodologies are required to fully establish the role of topical TXA in optimizing breast surgery outcomes.